Adolescents and adults aged 12-75 years old with chronic eczema (atopic dermatitis), may qualify to participate. Individuals must have moderate to severe disease, involving 10% of their body surface area, with an onset of symptoms at least 3 years prior to study start. A history (within 6 months) of inadequate response to treatment with topical medications or systemic treatment, or for whom topical treatments are otherwise medically inadvisable, is also required.
Participants will receive investigational oral medication (active study drug) or placebo during the initial treatment period. During the extension period, those individuals who previously received placebo will receive active study drug. Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided.
Study participation will last about 34 months and involve about 21 visits to the study centre.
Email Tina Craig, Clinical Research Coordinator at DermEffects to register.